Global Listeria monocytogenes Infections Treatment Market - Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016 - 2022, the Listeria monocytogenes infections treatment market was valued at USD 3,624.9 Mn in 2015, and is expected to reach USD 5,056.3 Mn by 2022, expanding at a CAGR of 4.74% from 2016 to 2022.
Browse Full Report Visit - http://www.acutemarketreports.com/report/listeria-monocytogenes-infections-treatment-market
Market Insights
Listeria monocytogenes, is an important pathogen in pregnant patients, neonates, elderly individuals, and immunocompromised individuals, although an uncommon cause of illness in the general population. Listeria monocytogenes is a bacterial pathogen capable of causing severe infections in humans, often with fatal outcomes. According to USFDA, published studies suggest that 1- 8% of humans may be intestinal carriers of Listeria. According to Unites States Department of Agriculture (USDA), Listeria causes about 280 cases of illness in newborns in a typical year, resulting in 60 deaths and stillbirths. Infants can be infected before birth, and this infection can cause serious disability in newborns. About 35 infants are disabled as a result of infection from Listeria each year. The key factors assisting the growth of Listeria monocytogenes infections treatment market are rise in prevalence of foodborne diseases, stringent laws and policies issued by FDA, rising demand for healthy and microbial-free food, and high public awareness related to foodborne diseases in developed countries.
Listeria monocytogenes, is an important pathogen in pregnant patients, neonates, elderly individuals, and immunocompromised individuals, although an uncommon cause of illness in the general population. Listeria monocytogenes is a bacterial pathogen capable of causing severe infections in humans, often with fatal outcomes. According to USFDA, published studies suggest that 1- 8% of humans may be intestinal carriers of Listeria. According to Unites States Department of Agriculture (USDA), Listeria causes about 280 cases of illness in newborns in a typical year, resulting in 60 deaths and stillbirths. Infants can be infected before birth, and this infection can cause serious disability in newborns. About 35 infants are disabled as a result of infection from Listeria each year. The key factors assisting the growth of Listeria monocytogenes infections treatment market are rise in prevalence of foodborne diseases, stringent laws and policies issued by FDA, rising demand for healthy and microbial-free food, and high public awareness related to foodborne diseases in developed countries.
Pipeline Analysis
The phase III drugs included in the pipeline analysis are Carbavance (The Medicines Company), Telavancin (Theravance Biopharma Antibiotics, Inc.), Daptomycin (Merck & Co.), Prulifloxacin (Merck & Co.), and DTaP-IPV/Hib combined vaccine (Sanofi S.A.). According to market experts, the diversity of the several molecule types in the biologic group shows a certain level of innovation, with newer avenues being explored in accounts of recent failures. Overall, late stage clinical trials have highlighted very few molecules that could potentially replace current treatments during the forecast period.
The phase III drugs included in the pipeline analysis are Carbavance (The Medicines Company), Telavancin (Theravance Biopharma Antibiotics, Inc.), Daptomycin (Merck & Co.), Prulifloxacin (Merck & Co.), and DTaP-IPV/Hib combined vaccine (Sanofi S.A.). According to market experts, the diversity of the several molecule types in the biologic group shows a certain level of innovation, with newer avenues being explored in accounts of recent failures. Overall, late stage clinical trials have highlighted very few molecules that could potentially replace current treatments during the forecast period.
Browse All Reports of This Category - http://www.acutemarketreports.com/category/pharmaceutical-market
Key Market Movements
• Rising prevalence of foodborne infections in developed and developing countries
• The incidence and prevalence of Listeria monocytogenes infections is high in pediatric and geriatric population
• Stringent regulatory policies applied by FDA and other government agencies across the world is expected to reduce the risk of infection outbreak
• Novel and developed treatments in pipeline are expected to assist the overall market growth of Listeria monocytogenes infections treatment market
• Rising prevalence of foodborne infections in developed and developing countries
• The incidence and prevalence of Listeria monocytogenes infections is high in pediatric and geriatric population
• Stringent regulatory policies applied by FDA and other government agencies across the world is expected to reduce the risk of infection outbreak
• Novel and developed treatments in pipeline are expected to assist the overall market growth of Listeria monocytogenes infections treatment market
Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology
Chapter 2 Executive Summary
2.1 Global Listeria monocytogenes Infections Treatment Market Portaiture
2.2 Global Listeria monocytogenes Infections Treatment Treament Market, by Drugs, 2015 (USD Mn)
2.3 Relativity Analysis: Global Listeria monocytogenes Infections Treatment Market, by Geography, 2015 & 2022 (USD Mn)
2.1 Global Listeria monocytogenes Infections Treatment Market Portaiture
2.2 Global Listeria monocytogenes Infections Treatment Treament Market, by Drugs, 2015 (USD Mn)
2.3 Relativity Analysis: Global Listeria monocytogenes Infections Treatment Market, by Geography, 2015 & 2022 (USD Mn)
Chapter 3 Listeria monocytogenes Infections Treatment Market: Market Dynamics and Outlook
3.1 Listeria monocytogenes Infections Treatment Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Listeria monocytogenes Infections Treatment Market, 2015 (Value %)
3.1 Listeria monocytogenes Infections Treatment Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Listeria monocytogenes Infections Treatment Market, 2015 (Value %)
Chapter 4 Global Listeria monocytogenes Infections Treatment Market, By Type of Infection
4.1 Preface
4.2 Bacteremia
4.3 Meningitis
4.4 Brain Abscess
4.5 Gastroenteritis
4.6 Endocarditis
4.7 Others
4.8 Pipeline Analysis
4.8.1 Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
4.8.1.1 Carbavance
4.8.1.2 Telavancin
4.8.1.3 Daptomycin
4.8.1.4 Prulifloxacin
4.8.1.5 DTaP-IPV/Hib combined vaccine
4.8.2 Tabular Representation of Phase II and I Drugs
4.1 Preface
4.2 Bacteremia
4.3 Meningitis
4.4 Brain Abscess
4.5 Gastroenteritis
4.6 Endocarditis
4.7 Others
4.8 Pipeline Analysis
4.8.1 Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
4.8.1.1 Carbavance
4.8.1.2 Telavancin
4.8.1.3 Daptomycin
4.8.1.4 Prulifloxacin
4.8.1.5 DTaP-IPV/Hib combined vaccine
4.8.2 Tabular Representation of Phase II and I Drugs
Chapter 5 Global Listeria Monocyogenes Infections Treatment Market, By Geography
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia Pacific
5.5 Rest of the World (RoW)
5.5.1 Latin America
5.5.2 Middle East and Africa
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia Pacific
5.5 Rest of the World (RoW)
5.5.1 Latin America
5.5.2 Middle East and Africa
To Get Complete Report @ http://www.acutemarketreports.com/report/listeria-monocytogenes-infections-treatment-market
Chapter 6 Company Profiles
6.1 Pfizer Inc.
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
7.1.3 Product Portfolio
6.1.4 News Coverage
6.2 Novartis AG
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Portfolio
6.2.4 News Coverage
6.3 Merck & Co.
6.1 Pfizer Inc.
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
7.1.3 Product Portfolio
6.1.4 News Coverage
6.2 Novartis AG
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Portfolio
6.2.4 News Coverage
6.3 Merck & Co.
About - Acute Market Reports :
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.
Our team consists of highly motivated market research professionals and they are accountable for creating the groundbreaking technology that we utilize in our search engine operations to easily recognize the most current market research reports online.
Contact Us :
Name : Chris Paul
ACUTE MARKET REPORTS
Designation : Global Sales Manager
Toll Free(US/CANADA): +1-855-455-8662
Email : sales@acutemarketreports.com
Website : http://www.acutemarketreports.com
Our Blog :- http://www.pdfdevices.com/
No comments:
Post a Comment